TCA
AQST icon

Transcend Capital Advisors’s Aquestive Therapeutics AQST Stock Holding History

Transcend Capital Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Buy
+37,928
New +$154K 0.01% 700

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Transcend Capital Advisors's AQST Position: Q1 2026 in Review

Transcend Capital Advisors opened a new position in Aquestive Therapeutics (AQST) in Q1 2026: 37,928 shares worth $157K. The stake represents 0.01% of the portfolio and ranks #700 among its holdings.

179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Transcend Capital Advisors held 37,928 shares of Aquestive Therapeutics worth $157K as of Q1 2026.
  • Aquestive Therapeutics was a new Transcend Capital Advisors position in Q1 2026.
  • Aquestive Therapeutics made up 0.01% of Transcend Capital Advisors's portfolio in Q1 2026, its #700 holding.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.